Bronchodilators Market is expected to hold a value of USD 2,484 Million by 2025 at a CAGR of 5.3%.

1
Bronchodilators Market is expected to hold a
value of USD 2,484 Million by 2025 at a CAGR of
5.3.
SAMPLE
FOR MORE INFO
2
Bronchodilators Market
Market Highlights According to MRFR analysis,
Bronchodilators Market is expected to register a
CAGR of 5.30 during the forecast period of 2019
to 2025 and is expected to reach USD 2,484
Million by 2025. Bronchodilators are medications
that make breathing easier by opening the airways
of the lung by relaxing bronchial muscles. They
are used to treat various respiratory problems
such as asthma, COPD, and other allergic
reactions that cause breathing problems. The
growth of the global bronchodilators market is
driven by various factors such as increase in
prevalence of pulmonary disorders, increasing
geriatric population and increasing mergers and
acquisitions by prominent players in the market.
However, side effects associated with
bronchodilators and government regulations
related to the safety efficacy of the
bronchodilators are projected to hamper the
growth of the global bronchodilators market. The
global bronchodilators market is currently
dominated by several market players. The key
players are involved in product launches and
strategic collaborations to strengthen their
market positions. For instance, in April 2019,
Cipla Technologies entered into agreement with
Pulmatrix Inc. to co-develop a formulation for
the treatment of allergic bronchopulmonary
aspergillosis (ABPA) in patients with
asthma. Request For Free Sample Report
https//www.marketresearchfuture.com/sample_reques
t/8453
3
Bronchodilators Market
Segmentation The global bronchodilators market
has been segmented based on drug type, disease,
mode of action, and route of administration. The
market, based on drug type, has been divided into
adrenergic drugs, anticholinergics, a
phosphodiesterase inhibitor, and combination
drugs. The adrenergic segment is likely to be
the largest during the review period as they are
the most potent bronchodilators approved for
clinical use in asthma and obstructive lung
disease. The combination drugs segment is
predicted to be the fastest-growing segment.
These combination drugs are used if COPD and
asthma are not controlled with monotherapy. These
combinations involving two long-acting
bronchodilators with differing modes of
action. The global bronchodilators market has
been segmented, on the basis of disease, into
asthma, COPD, and others. The asthma segment is
expected to hold the majority share of the
market, owing to the rise in patients affected
with asthma. The COPD segment is expected to be
the fastest-growing as bronchodilators are
primary treatment for chronic obstructive
pulmonary disease (COPD) as they help to
alleviate bronchial obstruction and airflow
limitation. Access Report Details _at_
https//www.marketresearchfuture.com/reports/bronc
hodilators-market-8453
4
Bronchodilators Market
Regional Analysis The market has been divided, by
region, into the Americas, Europe, Asia-Pacific,
and the Middle East Africa. The Americas are
expected to be the largest market owing to the
rising per capita healthcare expenditure. The
bronchodilators market in the Americas has
further been branched into North America and
Latin America, with the North American market
divided into the US and Canada. The European
bronchodilators market has been categorized as
Western Europe and Eastern Europe. The Western
European market has further been classified as
Germany, France, the UK, Italy, Spain, and the
rest of Western Europe. The bronchodilators
market in Asia-Pacific has been segmented into
Japan, China, India, South Korea, Australia, and
the rest of Asia-Pacific. Due to the increasing
prevalence of respiratory disorders and the
increasing pool of patient population, the market
in Asia-Pacific is expected to be the
fastest-growing. The bronchodilators market in
the Middle East Africa has been divided into
the Middle East and Africa. Key Players Some of
the key players in the Global Bronchodilators
Market are GlaxoSmithKline (UK), Novartis AG
(Switzerland), Merck Co., Inc. (US), Abbott
Laboratories (US), Boehringer Ingelheim GmbH
(Germany), AstraZeneca plc (UK), F. Hoffmann
LA-Roche AG (Switzerland), Teva Pharmaceutical
(Israel) and Pfizer Inc. (US) among
others.
5
ABOUT US
MARKET RESEARCH FUTURE At Market Research Future
(MRFR), we enable our customers to unravel the
complexity of various industries through our
Cooked Research Report (CRR), Half-Cooked
Research Reports (HCRR), Raw Research Reports
(3R), Continuous-Feed Research (CFR), and Market
Research Consulting Services. MRFR team have
supreme objective to provide the optimum quality
market research and intelligence services to our
clients. Our market research studies by products,
services, technologies, applications, end users,
and market players for global, regional, and
country level market segments, enable our clients
to see more, know more, and do more, which help
to answer all their most important questions. In
order to stay updated with technology and work
process of the industry, MRFR often plans
conducts meet with the industry experts and
industrial visits for its research analyst
members. For more information kindly visit
www.marketresearchfuture.com or contact us at
info_at_marketresearchfuture.com Copyright 2018
Market Research Future All Rights Reserved. This
document contains highly confidential information
and is the sole property of Market Research
Future. No part of it may be circulated, copied,
quoted, or otherwise reproduced without the
written approval of Market Research Future.
6
(No Transcript)